Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The TIL therapy pipeline is expanding rapidly to address advanced solid tumors with high unmet medical needs. Globally, cancer remains a major health burden, with an estimated 20 million new cancer cases and 9.7 million deaths in 2022, according to the International Agency for Research on Cancer. TIL therapy pipeline analysis by Expert Market Research highlights increasing investment in next-generation cell therapies, engineered TIL products, and combination immunotherapy strategies designed to improve durable clinical responses and survival outcomes.
Major companies involved in the TIL therapy pipeline analysis include Grit Biotechnology, Iovance Biotherapeutics, Inc., and others.
Leading drugs currently in the pipeline include OBX-115, IOV-4001, and others.
The TIL therapy pipeline is driven by expanding adoption of personalized cell therapies, encouraging clinical outcomes in solid tumors, advances in T-cell engineering, increasing oncology investments, and strategic collaborations accelerating next-generation immunotherapy development.
The TIL Therapy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into TIL therapy currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for TIL therapy. The TIL therapy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The TIL therapy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with TIL therapy guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to TIL therapy.

Read more about this report - Request a Free Sample
The TIL therapy pipeline is advancing rapidly as personalized cell therapies reshape the treatment landscape for advanced solid tumors. A major milestone was achieved in February 2024, when the U.S. FDA granted accelerated approval to Amtagvi (lifileucel) from Iovance Biotherapeutics for unresectable or metastatic melanoma, making it the first tumor-infiltrating lymphocyte (TIL) therapy and the first cellular therapy approved for a solid tumor. TIL therapy pipeline analysis by Expert Market Research highlights robust innovation in engineered TIL products, combination immunotherapies, and next-generation manufacturing technologies aimed at improving efficacy and expanding clinical applications.
Tumor-infiltrating lymphocyte (TIL) therapy is primarily indicated for advanced or unresectable melanoma, making its epidemiology closely aligned with this patient population. Globally, approximately 324,600 new melanoma cases and 57,000 melanoma-related deaths occur annually, with incidence increasing by 2-3% each year. The growing burden of advanced melanoma continues to expand the eligible population for TIL therapy. Following the FDA approval of lifileucel in 2024, adoption of TIL therapy is expected to increase as clinical evidence and treatment accessibility continue to improve.
This section of the report covers the analysis of TIL therapy drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The TIL therapy pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total TIL therapy clinical trials. Early Phase 1 (14.29%), Phase 1 (19.05%), Phase 2 (42.86%), Phase 3 (14.29%), and Phase 4 (9.52%). These findings indicate that Phase II represents the most active stage of clinical development, reflecting the strong emphasis on evaluating the efficacy and therapeutic potential of emerging TIL therapy candidates before they advance to late-stage clinical trials.
The drug molecule categories covered under the TIL therapy pipeline analysis include cell therapies, biologicals, and monoclonal antibodies. The TIL therapy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for TIL therapy. In June 2025, Five-year follow-up from the Phase II C-144-01 trial showed lifileucel achieved durable responses, a 31.4% objective response rate, and sustained overall survival in patients with advanced melanoma previously treated with immune checkpoint inhibitors.
The EMR report for the TIL therapy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed TIL therapy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in TIL therapy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for TIL therapy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of TIL therapy drug candidates.
OBX-115 is an investigational cell therapy biological comprising genetically engineered tumor-infiltrating lymphocytes (TILs) developed by Obsidian Therapeutics, Inc. for the treatment of advanced solid tumors. The therapy incorporates a regulated cytokine expression platform to enhance T-cell persistence, proliferation, and antitumor activity following infusion, aiming to improve the efficacy of conventional TIL therapy. The ongoing Phase I clinical study is expected to be completed in 2028. Obsidian Therapeutics specializes in engineered cell therapies using precision gene-regulation technologies to improve the safety and effectiveness of adoptive immunotherapies.
IOV-4001 is an investigational cell therapy biological being developed by Iovance Biotherapeutics, Inc. It consists of genetically modified tumor-infiltrating lymphocytes (TILs) engineered to enhance resistance to immune suppression within the tumor microenvironment, thereby improving durable antitumor responses. The candidate is being evaluated across advanced solid tumors as a next-generation TIL therapy. The ongoing clinical program is expected to be completed in 2029. Iovance Biotherapeutics is a leader in TIL-based immunotherapies, advancing personalized cell therapies for patients with difficult-to-treat cancers.
Lifileucel plus pembrolizumab is an investigational combination biological immunotherapy being developed by Iovance Biotherapeutics, Inc. The regimen combines lifileucel, an autologous TIL cell therapy, with the PD-1 inhibitor pembrolizumab to enhance T-cell expansion and sustain immune-mediated tumor destruction. This combination is designed to improve response rates and prolong disease control compared with either approach alone. The ongoing clinical study is expected to be completed in 2027. Iovance Biotherapeutics continues to pioneer TIL therapies through innovative clinical programs and strategic immunotherapy combinations.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The TIL Therapy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for TIL therapy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into TIL therapy collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.